Changchun GeneScience Pharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS20
PHASE 3 / 2-39
RECRUITING8
READOUTS ≤12 MONTHS8
READOUT SLIPPED >6 MO30%
Delay Index: of 10 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Changchun GeneScience Pharmaceutical Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| PEG-somatropin NCT02375620 |
P2 | Active, not recruiting | Short Stature Children Born Small for Gestational Age (SGA) | 96 | 2023-12-12 (+77 mo) |
| recombinant human follicle-stimulating hormone-CTP Fusion protein injection NCT06561594 |
P3 | Not yet recruiting | Idiopathic Hypogonadotropic Hypogonadism | 60 | 2024-11-23 |
| T Leuprolide Injectable Emulsion NCT06449027 |
P3 | Active, not recruiting | Breast Cancer Subjects | 211 | 2025-11 |
| GenSci048 NCT06189495 |
P2 | Recruiting | Systemic Sclerosis Associated Interstitial Lung Disease; Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD) | 30 | 2026-03-31 |
| Cabergoline tablets NCT07124221 |
P3 | Recruiting | Hyperprolactinemia | 382 | 2026-11-21 (+14 mo) |
| PEG-rhGH Injection NCT07260500 |
P2 | Recruiting | Short Stature Children Born Small for Gestational Age (SGA) | 72 | 2026-12-23 |
| Nano-crystalline Megestrol Acetate Oral Suspension NCT06961201 |
P3 | Not yet recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy | 94 | 2026-12-31 |
| Nano-crystalline Megestrol Acetate Oral Suspension NCT06961188 |
P3 | Not yet recruiting | Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity; Untreated With Systemic Therapy | 174 | 2027-06-30 |
| Nanocrystalline Megestrol Acetate NCT07356037 |
P3 | Not yet recruiting | Cachexia; Hepatocellular Carcinoma | 68 | 2027-06-30 |
| Nano-crystalline Megestrol Acetate Oral Suspension NCT06772428 |
P3 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors | 96 | 2027-06-30 |
| Nano-crystalline Megestrol Acetate Oral Suspension NCT07150663 |
P3 | Recruiting | Non-small Cell Lung Cancer | 134 | 2027-06-30 |
| GenSci120 150 mg NCT07423533 |
P2 | Recruiting | Rheumatoid Arthritis | 450 | 2027-09 |
| GenSci048 NCT07547995 |
P2 | Recruiting | Uveitis | 74 | 2027-12-14 |
| GenSci048 NCT06963177 |
P2 | Recruiting | Endometriosis-related Pain | 200 | 2028-05-15 |
| GenSci134 Injection NCT07450053 |
P1/2 | Not yet recruiting | Idiopathic Short Stature | 128 | 2028-07-18 |
| GenSci134 Injection NCT07450001 |
P1/2 | Not yet recruiting | Pediatric Growth Hormone Deficiency | 128 | 2028-07-18 |
| PEG-hGH Injection NCT07841678 |
P3 | Not yet recruiting | Small for Gestational Age | 105 | 2028-09 |
| GenSci136 for injection NCT07936084 |
P1/2 | Not yet recruiting | Patients With MG (gMG and oMG) | 72 | 2028-12 |
| PEG-somatropin NCT03255694 |
P2 | Active, not recruiting | Dwarfism | 360 | 2030-06 (+90 mo) |
| GS3-007a dry suspension NCT07264595 |
P1/2 | Recruiting | Pediatric Growth Hormone Deficiency | 88 | 2030-11 |